Resultado de búsqueda
Hace 4 días · Innovating in Health&Care. We’re building a world where complex diseases are prevented and cured, treatments are smarter and less invasive—and solutions are personal.
- Careers
Johnson & Johnson is an Affirmative Action and Equal...
- Products
Johnson & Johnson MedTech innovates at the intersection of...
- About J&J
At Johnson & Johnson, we believe health is everything. Our...
- Latest News
The Company1 enters agreement with Numab Therapeutics to...
- Personal Stories
Read all Johnson & Johnson personal stories . Nina...
- Our Heritage
4 Innovative Ways Johnson & Johnson Has Helped Protect the...
- Careers
Hace 2 días · Our Company. Every day, our more than 130,000 employees globally are building a world where complex diseases are prevented and cured, treatments are smarter and less invasive—and solutions are personal. At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress.
14 de may. de 2024 · COFEPRIS EMITE AUTORIZACIÓN PARA USO DE EMERGENCIA A VACUNA CONTRA COVID-19 AD26.COV2.S DE JANSSEN (JOHNSON & JOHNSON) | Comisión Federal para la Protección contra Riesgos Sanitarios | Gobierno | gob.mx. Comisión Federal para la Protección contra Riesgos Sanitarios. Blog.
Hace 4 días · Strengthens Position in Highest-Growth, Innovation-Oriented Segments of Cardiovascular Intervention Creates Greater Opportunity to Transform the Treatment Landscape for Cardiovascular Disease Johnson Johnson (NYSE: JNJ) today announced it has completed its acquisition of Shockwave Medical. Shockwave is now part of Johnson Johnson and will operate as a business unit within Johnson Johnson ...
Hace 4 días · Johnson & Johnson advances leadership in oncology innovation with more than 75 clinical study and real-world presentations at ASCO and EHA. Download. May 21, 2024. TREMFYA® (guselkumab) demonstrates superiority versus STELARA® (ustekinumab) in Phase 3 Crohn’s disease program. Download. May 20, 2024.
6 de may. de 2024 · Todas las noticias sobre Johnson & Johnson publicadas en EL PAÍS. Información, novedades y última hora sobre Johnson & Johnson.
28 de may. de 2024 · 05/28/2024. Download. The Company1 enters agreement with Numab Therapeutics to acquire its wholly owned subsidiary2 for the global rights to NM26, a Phase 2-ready investigational, first-in-class bispecific antibody targeting two clinically proven pathways in atopic dermatitis (AD)
